PRNewsWire
04 Aug 2026, 10:45 UTC · 1h ago
SOPHiA GENETICS Reports Second Quarter 2026 Results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
04 Aug 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
SOPHiA GENETICS signed two companion diagnostic programs with AstraZeneca, marking the first such programs in the company's history. — Securing a partnership with a major pharma player like AstraZeneca validates the company's AI platform and creates a high-value, scalable revenue stream.
+0.80The company reported 27% year-over-year revenue growth and a 27% improvement in adjusted EBITDA loss for Q2 2026. — Double-digit growth paired with narrowing losses demonstrates positive operational scaling and a path toward profitability.
+0.60SOPHiA GENETICS raised $57.5 million through an oversubscribed public offering in the second quarter. — The successful capital raise strengthens the balance sheet and provides the necessary runway to execute long-term growth strategies.
+0.40Continue reading
6 related stories
Search tags
The company saw significant volume growth in the U.S. (60%) and Liquid Biopsy (70%) during the quarter. — Strong regional and product-specific growth indicates increasing market adoption of their core precision medicine offerings.
+0.30Which stocks this story touches
The company reported 27% year-over-year revenue growth, reduced EBITDA loss, and secured two new companion diagnostic programs.
The company entered into two new companion diagnostic programs with SOPHiA GENETICS, indicating business expansion.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
